Atea Pharmaceuticals (NASDAQ: AVIR) announced that its hepatitis C drug combination bemnifosbuvir/ruzasvir (BEM/RZR) met both primary and secondary endpoints in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA